Imaging Findings and Value of CT and DCE-MRI in Monitoring Denosumab Therapy of Giant Cell Tumors of Bone

Purpose or Learning Objective: Our aim was (1) to evaluate the value of computed tomography (CT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for monitoring denosumab therapy of giant cell tumor of bone (GCTB); (2) to describe imaging findings at diagnosis and during treatment; and (3) to offer an overview of good and poor response, relapse, and therapeutic complications.

Methods or Background: Twelve patients (eight men, four women; mean age: 33.8 years) with GCTB (four spine, eight limbs) were monitored every 6 months with alternately CT and DCE-MRI (mean follow-up: 4.8 years). Response, relapse, and complications were assessed on imaging studies and semiquantitative measurements.

Results or Findings: On CT, good responders showed progressive reossification of osteolytic areas (mean increase: 12 HU/month), a reduction of tumor volume and soft tissue mass (mean decrease: 0.07 cm³/month), and cortical remodeling. On MRI, first a reduction in contrast enhancement (mean decrease of signal intensity: 55 AU/month), surrounding bone marrow edema (mean decrease of signal intensity: 8 AU/month), and volume were observed. Next, focal necrosis, fatty infiltration, and subsequent progressive reossification and sclerosis of the osteolytic area appeared. On DCE-MRI, the time-intensity curve type evolved gradually from a type IV curve with high first pass, high amplitude, and steep washout rate to an intermediate type III or V curve, and subsequently to a slow type I or II curve. A reduction in wash-in slope, maximum signal intensity, area under the curve, and amplitude of wash-in was observed, together with an increase in arrival time and time to peak. A decrease in Ktrans, initial area under curve, and amplitude A was observed, together with an increase of Ve and Kep (extended Tofts/Brix models).

Patients with poor response or relapse showed the inverse findings of the good responders on CT and DCE-MRI.

Regarding evolution in time, one patient with an initial good response showed a new cortical breakthrough and a new rapidly growing enhancing soft tissue mass with medullary compression and extensive bone marrow edema. Biopsy revealed a highly cellular high-grade conventional osteosarcoma with small interstitial space.

Conclusion: Denosumab is effective in inoperable GCTB and in operable cases with significant morbidity. The evolution of CT and DCE-MRI allows effective continuous monitoring of GCTB and detection of early and late response, relapse, therapy failure, and malignant transformation to osteosarcoma.

 

MissingLinkText

No conflict of interest has been declared by the author(s).

Publication History

Article published online:
02 June 2022